Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 41Carcinoma, Non-Small-Cell Lung 35Carcinoma, Renal Cell 26Neoplasm Metastasis 19Lung Neoplasms 18Carcinoma, Hepatocellular 15Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Neoplasms 9Carcinoma, Transitional Cell 9Multiple Myeloma 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Head and Neck Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Hodgkin Disease 6Advanced Cancer 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Skin Neoplasms 4Recurrence 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Uveal Melanoma 3

Interventions

Ipilimumab 4tremelimumab 1tilsotolimod 1durvalumab 1Vemurafenib 1Vaccination 1Surgical Procedures, Operative 1Nivolumab 1Melphalan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diabetes Mellitus, Insulin-Dependent, 12 × Nivolumab × Clear all
NCT03354962 2020-12-04

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Institut Claudius Regaud

Phase 1/2 Terminated
6 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡